Guangdong Xinyaguang Cable
001382
Haimo Technologies Group Corp.
300084
Shaoyang Victor Hydraulics
301079
4
KLT
831689
5
Qingdao Tianneng Heavy Industries
300569
US Stock MarketDetailed Quotes
XCUR Exicure
- 14.0500
- +0.4900+3.61%
Close Mar 21 16:00 ET
- 15.0000
- +0.9500+6.76%
Post 18:43 ET
88.76MMarket Cap-2.96P/E (TTM)
14.5362High14.0500Low16.16KVolume14.3000Open13.5600Pre Close229.60KTurnover0.35%Turnover RatioLossP/E (Static)6.32MShares36.000052wk High13.11P/B64.49MFloat Cap1.440052wk Low--Dividend TTM4.59MShs Float576.0000Historical High--Div YieldTTM3.59%Amplitude1.4400Historical Low14.2080Avg Price1Lot Size
Market Insights
Discussing
Trump 2.0 Era: How will global markets evolve?
🎙️Discussion: 1. How will tariff policies affect the movement of key assets such as U.S. stocks, gold, and Bitcoin? 2. Given this context,
Moo Live
Jan 23 16:54
MicroStrategy Q4 2024 earnings conference call
Exicure Stock Forum
Exicure's New Cancer Patent Breakthrough Powers Multiple Myeloma Clinical Trial
1. NFA (Not Financial Advice!) This is NOT a BUY or SELL advice.
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow)
7. NEVER be a blind follower.
LASTLY, If you do...
1. NFA (Not Financial Advice!) This is NOT a BUY or SELL advice.
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow)
7. NEVER be a blind follower.
8. With regards t...
📊⚡️📊
Dow Jones· 1 min ago
Exicure, Inc. Announces Purchase Agreement with GPCR Therapeutics Inc.
Wednesday, 22nd January at 4:01 pm
Exicure, Inc. (NASDAQ: XCUR, "the Company", "Exicure")), today announced that on January 19, 2025, Exicure Inc. ("the Company") entered into a Share Purchase Agreement with GPCR Therapeutics Inc., a Korean corporation ("GPCR"), pursuant to which the Company acquired from GPCR all of the issued and outstanding equity securities of GPCR Therapeutics USA Inc., a Californi...
📊⚡️📊
Exicure (XCUR) has signed an MOU with GPCR Therapeutics to acquire its US subsidiary, GPCR USA, and collaborate on drug development pipelines. The deal includes technology transfer of GPCR's CXCR4 inhibitor, currently in Phase 2 clinical trials, with an estimated market size of $1-2 billion annually. The acquisition targets multiple myeloma and acute myeloid leukemia (AML) treatments.
The company has secured total funding of $12 million ($8.7M on Dec 24, $2M on Dec 9, ...
No comment yet